Texas arrests midwife for allegedly providing illegal abortions
March 17 (Reuters) - Texas arrested a midwife for allegedly providing illegal abortions and illegally operating a network of clinics in the Houston area, the state attorney general said on Monday.
Texas has heavily restricted abortion since the federal right to the procedure was overturned in a Supreme Court ruling in 2022.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
In addition to arresting Maria Margarita Rojas, officials have filed for a temporary restraining order to shut down the clinics. The attorney general has the ability to seek penalties of at least $100,000 per violation, the attorney general's statement said.
"Texas law protecting life is clear, and we will hold those who violate it accountable," Attorney General Ken Paxton said.
Rojas owns multiple clinics that used unlicensed individuals who falsely presented themselves as licensed medical professionals, the statement said.
Clinicas Latinoamericanas, which operates three locations named by the attorney general, did not immediately respond to a request for comment from Reuters.
Texas prohibits abortions unless the pregnancy places the woman at risk of death or "substantial impairment of a major bodily function."
A New York doctor in January was indicted by a grand jury in Louisiana for prescribing an abortion pill taken by a teenager there.
The U.S. Supreme Court in June 2022 overturned the landmark 1973 Roe v. Wade ruling that recognized women's constitutional right to abortion.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
8 hours ago
- Reuters
Novo's Ozempic, Wegovy linked to rare cases of dangerous eye disorder, EMA says
June 6 (Reuters) - The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's ( opens new tab popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition. Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, the regulator said on Friday. The EMA, which started its review in December, said the use of the drugs is linked to about twofold increase in the risk of developing the condition compared to people not taking the medicine. NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma. Studies have linked semaglutide to NAION in the past. But this is the first time a regulator has made the link. Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. A large study of nearly 350,000 diabetics published earlier this year had showed that the risk of developing NAION more than doubled after long-term use of semaglutide, compared to patients taking medicines from other classes. The EMA said it has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials and post-marketing surveillance. It has recommended the drugmaker to update prescribing information for medicines containing semaglutide to include NAION as a side effect with a frequency of "very rare". The U.S. Food and Drug Administration did not immediately respond to a Reuters request for comment.
Reuters
8 hours ago
- Reuters
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
June 6 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) Adding Roche's (ROG.S), opens new tab immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death compared to chemotherapy alone, according to trial data presented at recent medical meeting. Patients in the study had tumors with a genetic defect known as deficient DNA mismatch repair, or dMMR. About 15% of colon cancer patients have dMMR tumors, which do not respond well to chemotherapy. "The findings from our study represent a major advance in the adjuvant treatment of dMMR stage 3 colon cancer and will now change the treatment for this type of cancer," study leader Dr. Frank Sinicrope of the Mayo Clinic in Rochester, Minnesota said in a statement. The data, opens new tab were presented at the ASCO meeting that concluded earlier this week. The trial enrolled 712 patients with dMMR stage 3 colon cancer that had been surgically removed and who had cancer cells in their lymph nodes. Half of the study participants received chemotherapy along with Tecentriq, which activates the immune system to attack and kill cancer cells, for six months, followed by the immunotherapy alone for another six months. The other half of the patients received chemotherapy for 12 months. The benefit of Tecentriq was seen even in the oldest patients and those at particularly high-risk. "It's extremely rewarding to be able to offer our patients a new treatment regimen that can reduce the risk of recurrence and improve their chances of survival," Sinicrope said. As patients recover after a minimally invasive heart procedure, they might be better off continuing to take a certain type of blood-thinning drug to help prevent a heart attack or stroke, instead of continuing with the traditional aspirin, a new study suggests. Early after percutaneous coronary intervention (PCI) - a procedure to prop open blocked arteries either after a heart attack, or to prevent one - patients often receive dual anti-clotting therapy with both a P2Y12 inhibitor such as clopidogrel, the generic version of Plavix, or AstraZeneca's (AZN.L), opens new tab Brilinta (ticagrelor), and aspirin. After several months, patients are usually switched from dual therapy to lifelong daily aspirin use. But pooled data looking at patients who took part in five earlier clinical trials found that continuing to prescribe the P2Y12 inhibitors and stopping the aspirin was associated with lower rates of death, heart attack and stroke compared with continuing the aspirin, with no increased risk of major bleeding, researchers reported in The BMJ, opens new tab. Overall, the trials involved 16,117 patients who received either a P2Y12 inhibitor or aspirin after completing dual therapy following PCI. After an average follow-up period of around 4 years, P2Y12 inhibitor therapy was associated with a 23% lower risk of a composite of heart-related death, heart attack, or stroke, compared with aspirin, with no significant difference in major bleeding. That translates into one prevented cardiovascular death, heart attack, or stroke for every 46 patients taking a P2Y12 inhibitor instead of aspirin after dual therapy. Overall, the findings suggest that P2Y12 inhibitor drugs should be preferred over aspirin 'due to reductions in major adverse cardiac and cerebrovascular events without increasing major bleeding in the medium term,' according to an editorial published with the study. But the editorial said that since patients are advised to continue the post-PCI therapy for life, large trials directly comparing the different strategies with longer follow up are needed. Some diabetes and weight-loss drugs from the class known as GLP-1 agonists were linked with a small but elevated risk for an age-related eye disease in patients with diabetes, according to a study published on Thursday in JAMA Ophthalmology, opens new tab. In 139,000 patients with diabetes, including 46,334 who had been using the GLP-1 drugs semaglutide or lixisenatide, researchers identified 181 new cases of neovascular age-related macular degeneration, also known as wet AMD. Wet AMD is a degenerative eye disease marked by the abnormal growth of blood vessels under the retina that leak fluid or blood and can lead to blindness. The risk of developing AMD during up to three years of follow-up was low, at 0.2% in GLP-1 users versus 0.1% in non-users. Still, the researchers point out, after accounting for patients' individual risk factors, the odds of AMD were doubled with at least six months of GLP-1 use and tripled in patients with the longest duration of use. Semaglutide is the active ingredient in the widely used Novo Nordisk ( opens new tab drugs Ozempic and Wegovy, while lixisenatide is the main ingredient in Sanofi's ( opens new tab discontinued Adlyxin. GLP-1 drugs have also been associated with higher risks for an eye condition known as nonarteritic anterior ischemic optic neuropathy, or NAION. Researchers did not have information about the dose, route of administration, or frequency of administration of the medications used in the study. Even with that information, the study could not have proved cause and effect. At least one earlier study with longer follow up reported that GLP-1 use was linked with a lower, rather than higher, risk for AMD. 'Our findings are not directly contradictory' with that earlier report, said study leader Dr. Reut Shor of the University of Toronto. 'Factors such as timing and duration of exposure, disease stage, and patient characteristics may all influence outcomes," Shor said. "Our results add another layer to the emerging understanding of this complex relationship and emphasize the need for further research to clarify these trends.' (To receive the full newsletter in your inbox for free sign up here)
Reuters
9 hours ago
- Reuters
Russia says its strike against Kyiv and other centres was a response to Ukrainian 'terrorist acts'
MOSCOW, June 6 (Reuters) - Russia's Defence Ministry said on Friday that its forces had carried out a massive and successful strike on military and military-related targets in Ukraine overnight in response to what it called Ukrainian "terrorist acts" against Russia. Russia's military released the statement after Ukrainian officials said Russia had launched an intense missile and drone barrage at Kyiv, the Ukrainian capital, in the early hours of Friday and that three people had been killed. Russia has accused Ukraine of being behind a deadly bomb attack on a bridge over a railway line in western Russia at the weekend that was blown up just as a train carrying 388 passengers to Moscow was passing underneath. Seven people were killed and 155 injured in the incident which Kyiv has not taken responsibility for. Separately, Ukraine attacked Russian nuclear-capable bomber planes at airfields over the same weekend, causing significant damage. President Vladimir Putin told U.S. President Donald Trump this week that he would retaliate. The Kremlin confirmed on Friday that the big overnight strikes had been a response to what it called Kyiv's "acts of terrorism". "Everything that is taking place within the framework of the special military operation (in Ukraine), everything that is being done by our military on a daily basis, is a response to the actions of the Kyiv regime, which has acquired all the characteristics of a terrorist regime," Kremlin spokesman Dmitry Peskov told reporters. Ukraine has frequently accused Russia of terrorism, citing attacks in which thousands of civilians have been killed. Both sides say they do not target civilians. The Russian military said in its statement that it had used long-range weapons to strike Ukraine. "In response to terrorist acts by the Kyiv regime, the Russian Armed Forces carried out a massive strike overnight with long-range air, sea and land-based precision weapons," the ministry said. It said the strike had targeted "Ukrainian design bureaus, enterprises for the production and repair of weapons and military equipment, assembly workshops for strike drones, flight training centres, and Ukrainian armed forces weapons and military equipment depots." "The objective of the strike was achieved. All designated targets were hit." Russian troops had also taken control of the settlement of Fedorivka in eastern Ukraine, the Defence Ministry said. Reuters could not independently confirm the battlefield report.
